Boston, MA 01/22/2014 (wallstreetpr) – The emerging biopharmaceutical company Alcobra Ltd (NASDAQ:ADHD) is focused on the development and commercialization of MG01CI which is targeted for the treatment of cognitive dysfunction. As the company seeks to position itself in the biopharm market, more so to give a head-start to its drug candidate, it has taken the step to hire an industrial veteran in David Baker as Chief Commercial Officer.
As the Chief Commercial Officer, Mr. Baker will be responsible for all efforts aimed at promoting the company’s biopharm products. His activities will be first concentrated in the pre-commercial developments towards attainment of brand awareness in the medical community.
The biopharm industry is a lucrative market to play in, but the best of the market is preserved for companies which can devise the winning strategies. This is why Alcobra Ltd (NASDAQ:ADHD) is keen on having Mr. Baker at its commercial desk. Mr. Baker has a wealth of knowledge in biopharm product promotions given the longevity of his service in the industry.
Alcobra Ltd (NASDAQ:ADHD) will be looking to Mr. Baker to evaluate new opportunities and support the company’s investor and public relation efforts. Of course, the company needs good relation with the public, investors and stakeholders in the industry in order to penetrate the market faster.
In promoting MG01CI, Mr. Baker gets down to work on the prelaunch activities around the product which include branding and positioning. The top leadership of Alcobra Ltd (NASDAQ:ADHD) has expressed confidence in Mr. Baker, citing his right skill set to execute on matters commercial.
And Mr. Baker is not ready to disappoint. He recently said that he is looking forward to helping Alcobra Ltd (NASDAQ:ADHD) bring its innovative products to the market and more so, achieving its strategic goals of being a world-class player in the biopharm industry.
The latest development in Alcobra Ltd (NASDAQ:ADHD) have been clearly popular with investors who have become very enthusiastic trading the stock. The stock is up significantly with gains in every single session since good news started emerging from the company. A share of Alcobra Ltd (NASDAQ:ADHD) is trading around $21.90, with a one year range of $6.50 – $26.96.